IGF-1 LR3: Long-Acting Insulin-Like Growth Factor Research

What is IGF-1 LR3?

IGF-1 LR3 (Long Arg3 IGF-1) is an 83-amino-acid analogue of insulin-like growth factor 1 — engineered to extend preclinical half-life by orders of magnitude relative to native IGF-1 (70 residues, ~7649 Da). The extended structure includes a 13-residue Arg-Glu3 N-terminal extension plus an Arg substitution at the native position 3 (replacing Glu3). With a molecular weight of 9111.5 Da and a preclinical half-life of approximately 20-30 hours (vs 12-15 minutes for native IGF-1), the compound is the standard research tool for sustained IGF-1 receptor signalling studies. Researchers can access IGF-1 LR3 research peptide at Advanced Peptide Science.

Research Background and the IGFBP Problem

Native IGF-1 is rapidly sequestered in circulation by IGF-binding proteins (IGFBP-1 through IGFBP-6) — approximately 99% of circulating native IGF-1 is bound to IGFBPs at any given time, leaving only ~1% as free IGF-1 available for receptor binding. The IGFBP-bound fraction is functionally inactive for direct receptor signalling. The IGFBP sequestration is a major confounder in IGF-1 research, since exogenous native IGF-1 is rapidly absorbed into the IGFBP pool and its receptor-relevant free concentration is determined by IGFBP dynamics rather than by the dose administered. The IGF-1 LR3 modifications specifically target IGFBP binding affinity reduction.

Mechanism of Action

Mechanism research investigates IGF-1 LR3 binding at the IGF-1 receptor (IGF-1R) — a receptor tyrosine kinase that initiates downstream PI3K/Akt and MAPK signalling cascades. The downstream pathways drive cell proliferation, anti-apoptotic signalling, and anabolic gene expression programmes. The research advantage of IGF-1 LR3 lies in the reduced IGFBP sequestration: more administered compound remains as free, receptor-binding-competent ligand, enabling clean dose-response research and sustained receptor occupancy not achievable with native IGF-1.

Key Research Findings

Reduced IGFBP Binding

The N-terminal Arg-Glu3 extension and Glu3Arg substitution dramatically reduce affinity for the IGF-binding proteins. The 13-residue N-terminal extension introduces steric hindrance to IGFBP binding; the Glu3Arg substitution alters a critical IGFBP-binding determinant. The combined modifications preserve IGF-1R binding while reducing IGFBP binding by orders of magnitude.

Extended Half-Life

The reduced IGFBP sequestration plus altered renal clearance kinetics extend preclinical half-life from 12-15 minutes (native IGF-1) to approximately 20-30 hours (IGF-1 LR3). This is one of the largest pharmacokinetic extensions in any peptide-modification research lineage.

Myosatellite Cell Research

IGF-1 LR3 research applications include myosatellite cell proliferation studies, where the extended receptor occupancy enables clean dose-response investigation of IGF-1 receptor-driven cell proliferation kinetics not achievable with rapidly-cleared native IGF-1.

Research Applications

IGF-1 LR3 occupies a distinctive position in the Growth Hormone & Performance category as a downstream IGF-1 axis research compound — distinct from the upstream GHRH analogues (Sermorelin, Tesamorelin) and GHRPs (GHRP-6, GHRP-2, Hexarelin) that drive endogenous IGF-1 production through pituitary GH stimulation. Comparative research using IGF-1 LR3 (direct IGF-1R activation) vs upstream GHRH/GHRP compounds (indirect IGF-1R activation via GH-induced hepatic IGF-1 synthesis) enables research dissecting direct vs indirect IGF-1 axis pharmacology.

Research Specifications

Molecular Weight	9111.5 Da
Sequence	83-amino-acid IGF-1 analogue (native 70 + N-terminal Arg-Glu3 extension + Glu3Arg substitution)
Receptor Target	IGF-1 receptor (receptor tyrosine kinase)
Downstream Pathways	PI3K/Akt + MAPK anabolic signalling
Preclinical Half-Life	Approximately 20-30 hours (vs 12-15 min for native IGF-1)
Format	Lyophilized powder in sterile vial
Purity	≥ 99% (HPLC verified)
Storage	-20 °C, protect from light

Frequently Asked Questions

What does LR3 mean in IGF-1 LR3?

LR3 stands for “Long Arg3” — referring to the 13-residue Arg-Glu3 N-terminal extension plus the Arg substitution at the native position 3 (replacing Glu3). These two modifications reduce IGFBP binding affinity and extend preclinical half-life dramatically.

How does IGF-1 LR3 differ from native IGF-1?

Native IGF-1 (70 residues, ~7649 Da, half-life 12-15 min) is rapidly sequestered by IGFBPs in circulation. IGF-1 LR3 (83 residues, 9111.5 Da, half-life 20-30 hours) has dramatically reduced IGFBP binding, providing sustained free-ligand availability for IGF-1R activation.

Where can researchers source IGF-1 LR3?

IGF-1 LR3 research peptide is available at Advanced Peptide Science at 99%+ HPLC-verified purity in 0.5mg and 1mg vials plus kit configurations.

Is IGF-1 LR3 approved for human use?

Advanced Peptide Science supplies IGF-1 LR3 exclusively for in vitro and in vivo scientific research. Not for human consumption. Research use only.

---

For Research Use Only. Not for human consumption. Not intended to diagnose, treat, cure, or prevent any disease.